Pharmaceutical Research and Manufacturers of America

Pharmaceutical Research and Manufacturers of America
Name	Pharmaceutical Research and Manufacturers of America
Abbreviation	PhRMA
Formation	1958
Type	Trade association
Headquarters	Washington, D.C.
Region served	United States
Leaders	Chief Executive Officer

Pharmaceutical Research and Manufacturers of America is a trade association representing leading firms in the biopharmaceutical sector in the United States. It advocates for policies affecting Food and Drug Administration, United States Congress, Centers for Medicare & Medicaid Services, National Institutes of Health, and global regulatory frameworks such as the European Medicines Agency and World Health Organization. The organization engages with stakeholders including President of the United States, state governors, patient advocacy groups like American Cancer Society, and healthcare providers such as the American Medical Association.

History

Founded in 1958 during an era of postwar expansion in the pharmaceutical industry, the association evolved from earlier industry groups that included executives from Merck & Co., Pfizer, Eli Lilly and Company, and GlaxoSmithKline. Throughout the 1960s and 1970s it interacted with legislative milestones including the Hatch-Waxman Act and worked alongside regulators during crises tied to events like the Thalidomide aftermath. In the 1980s and 1990s the association engaged in debates over Bayh–Dole Act implementation, intellectual property precedents from the United States Supreme Court, and biotechnology commercialization involving firms such as Genentech and Amgen. The 21st century brought controversies tied to pricing from companies like Turing Pharmaceuticals and legal confrontations involving state attorneys general and federal agencies including the Department of Justice.

Mission and Activities

The association's stated mission centers on supporting research and development by member companies, interacting with regulators such as the Food and Drug Administration and funders such as the National Institutes of Health, and promoting public policy supportive of medical innovation. Activities include advocacy before the United States Congress, participation in stakeholder coalitions with groups like the Biotechnology Innovation Organization, and public communications involving think tanks such as the Brookings Institution and Heritage Foundation. It organizes conferences with industry leaders from Johnson & Johnson, Roche, Novartis, and academic partners like Johns Hopkins University and Harvard Medical School to discuss clinical trial design, regulatory science, and market access.

Membership and Governance

Membership comprises major biopharmaceutical companies including multinational firms such as AstraZeneca, Bristol Myers Squibb, Sanofi, and Takeda Pharmaceutical Company. Governance is conducted via a board of directors made up of chief executives and senior executives from member companies, often interacting with counsel from law firms like Covington & Burling and consultants from firms such as McKinsey & Company and Ernst & Young. Executive leadership liaises with policymakers including members of the United States Senate and committees such as the United States House Committee on Energy and Commerce. Annual meetings attract representatives from research institutions such as Massachusetts Institute of Technology and funding organizations such as the Bill & Melinda Gates Foundation.

Policy Positions and Lobbying

The association advocates positions on patent protection relating to the United States Patent and Trademark Office, pricing policies affecting Centers for Medicare & Medicaid Services reimbursement, and regulatory pathways administered by the Food and Drug Administration and the European Medicines Agency. It lobbies Congress, the Office of Management and Budget, and state legislatures on issues including exclusivity provisions tied to the Biologics Price Competition and Innovation Act and importation policies debated during administrations such as that of the Donald Trump presidency and the Joe Biden administration. The association files amicus briefs in litigation before the United States Supreme Court and engages in public campaigns responding to initiatives from advocacy groups like Public Citizen and Families USA.

Legal and Controversies

The organization and its members have been involved in litigation concerning pricing, patent settlements challenged under antitrust law by the Federal Trade Commission and state attorneys general, and disclosure controversies investigated by the United States Department of Justice. High-profile disputes have referenced firm actions by companies such as Valeant Pharmaceuticals International and Mylan N.V., and have intersected with oversight by congressional committees including the United States Senate Committee on Finance and United States House Committee on Oversight and Accountability. The association has responded to criticism from media outlets such as The New York Times and The Washington Post and to campaigns by patient groups like Patients for Affordable Drugs Now.

Publications and Research Programs

The association publishes policy reports, white papers, and analyses on topics ranging from biopharmaceutical innovation metrics to health technology assessment used by entities such as the Institute for Clinical and Economic Review. It funds research collaborations with academic centers including University of California, San Francisco and participates in data initiatives involving real-world evidence from healthcare systems like Kaiser Permanente and registries maintained by organizations such as National Cancer Institute. Publications include economic impact studies, position papers on clinical trial modernization with regulators like the Food and Drug Administration, and safety communications coordinated with postmarketing surveillance programs such as the Vaccine Adverse Event Reporting System.

Category:Trade associations based in the United States Category:Pharmaceutical industry